Mark Bard, with DHC Group, and Shwen Gwee, founder of #GenAI4Pharma, discussed the potential of AI in the pharmaceutical industry, with a focus on content generation, startups, intelligent automation, patient support programs, and its impact on the Electronic Medical Record (EMR). They also explored the potential of generative AI to create operational efficiencies across various functions in the industry, including drug development, creative and educational content, and patient support programs. The conversation also discussed the importance of regulatory compliance in the use of generative AI and commercial content and programs.